Regeneron Securities Fraud Lawsuit, Were You Affected? — Cheatham v. Regeneron Pharmaceuticals, Inc., No. 7:26-cv-06026

September 14, 2026. That’s the deadline to ask a federal court to lead the Regeneron securities fraud case, not to file a claim, since none exists yet. Investors who bought REGN stock between August 1, 2025 and May 15, 2026 say the company downplayed real risk in its cancer drug trial before the truth came out. Here’s what that deadline actually controls, and what doesn’t require you to do anything at all.

Regeneron Securities Fraud Lawsuit — Key Facts

Lawsuit Filed	July 16, 2026
Defendant	Regeneron Pharmaceuticals, Inc. and certain named officers
Alleged Harm	Misleading investors about the risk facing the Phase III Fianlimab-Libtayo melanoma trial
Law Alleged	Sections 10(b) and 20(a) of the Securities Exchange Act of 1934; SEC Rule 10b-5
Who Is Affected	Investors who purchased REGN common stock between August 1, 2025, and May 15, 2026
Court & Case Number	U.S. District Court, Southern District of New York — No. 7:26-cv-06026
Current Stage	Complaint filed; competing lead plaintiff motions due before appointment
Lead Plaintiff Deadline	September 14, 2026
Settlement Status	No settlement exists. No claim form exists.
Last Updated	August 3, 2026

Who Is Regeneron and Why Are They Being Sued Over a Melanoma Drug Trial?

Regeneron is a biotech giant behind Eylea, Dupixent, and Libtayo, and it was betting on fianlimab, a LAG-3 inhibitor, paired with Libtayo as a new first-line treatment for advanced melanoma. That combination needed to beat Merck’s Keytruda alone to matter commercially. Investors say Regeneron told the market the study was on track when its own data was already showing trouble.

What Did Regeneron Tell Investors, and When Did It Fall Apart?

The lawsuit centers on two moments, not one, and that’s the part most coverage glosses over. On April 29, 2026, during Regeneron’s first-quarter earnings call, the company disclosed it had expanded the patient population eligible for its progression-free survival analysis, a mid-study protocol change. REGN shares fell $45.41, or 6.21%, that day, closing at $686.36, down from a Class Period high of $731.77.

Then, on May 15, 2026, Regeneron announced after the market closed that the “Phase 3 Trial of Fianlimab…did not reach statistical significance for the primary endpoint” against pembrolizumab monotherapy. The stock dropped again, closing near $629.68. Combined, that’s a $102.09 per-share slide, about 13.95%, from the Class Period high. Regeneron itself confirmed in a subsequent SEC filing that a shareholder had filed a putative class action over these events.

That two-step drop is the whole case. A partial disclosure in April, then the full one in May, and investors say both should have come sooner.

Are You Part of the Regeneron Securities Fraud Lawsuit?

Here’s exactly how to know if this case includes you.

• Investors who purchased REGN common stock between August 1, 2025 and May 15, 2026
• Anyone holding REGN options or other REGN securities acquired during that same window
• Institutional and individual shareholders alike, regardless of how many shares
• People who bought REGN stock only after May 15, 2026, when the trial failure was already public, do not qualify for this class

Regeneron Investors Outside New York — Are You Still Covered?

Yes. This is a federal securities case under the Exchange Act, so it applies nationwide no matter where you live or where your brokerage account is based.

Not sure if you qualify for the Regeneron securities fraud lawsuit? A free consultation with a securities fraud attorney can walk through your trade dates and losses before the September 14 deadline.

Related article: Big Al’s Noncompetition Settlement, Were You Affected? — Lazova-Fast v. Big Al’s, Inc., No. 25-2-01504-06

What Are Regeneron Investors Asking the Court to Award?

The complaint seeks damages equal to the losses investors suffered when the stock fell on the corrective disclosures, on behalf of everyone who bought during the Class Period. No money yet. No claim form yet.

What Could Regeneron Investors Receive If This Case Settles?

Impossible to predict this early. Securities fraud cases like this typically take two to four years to move from filing to any resolution, and outcomes depend on discovery, expert testimony on damages, and whatever a judge or jury eventually decides about what Regeneron actually knew in April and May 2026.

What Should Regeneron Investors Do Right Now?

1. Most investors are automatically included. You don’t need to file anything to remain part of the class.
2. Save your brokerage statements and trade confirmations showing REGN purchases and sales between August 2025 and May 2026.
3. Note your exact purchase and sale dates and prices, since damages calculations run off those numbers directly.
4. The lead plaintiff deadline is September 14, 2026. Missing it doesn’t remove you from the class; it just means you can’t ask to direct the litigation.
5. Watch the SDNY docket for Case No. 7:26-cv-06026 for the lead plaintiff appointment and any motion to dismiss.
6. If your losses are substantial, talk to a securities fraud attorney about whether petitioning to be lead plaintiff makes sense for you.

You’ll likely see several law firms issue near-identical “alerts” about this case. That’s normal in securities litigation; firms compete for the lead role, and a judge picks one to represent everyone. No firm has an exclusive claim on your case just because they emailed you first.

Regeneron Securities Fraud Lawsuit — Frequently Asked Questions, No. 7:26-cv-06026

Is there a class action lawsuit against Regeneron for securities fraud right now?

Yes. Cheatham v. Regeneron Pharmaceuticals, Inc., et al., No. 7:26-cv-06026, was filed July 16, 2026, in the Southern District of New York.

Do I need to do anything right now to be part of the Regeneron lawsuit? 

No. If you bought REGN stock during the Class Period, you’re already a class member. Only investors seeking the lead plaintiff role need to act before September 14, 2026.

When will the Regeneron securities fraud case settle? 

UNVERIFIED. The case was just filed in July 2026; no motion to dismiss ruling or settlement timeline exists yet.

Can I file my own lawsuit against Regeneron instead of joining the class? 

Yes, investors can opt out later once a class is certified, though most shareholders find it more efficient to remain in the class action.

How will I find out if the Regeneron lawsuit settles?

 Court-approved notice goes to known shareholders once a settlement or judgment is reached; you can also track the SDNY docket directly.

What does the lead plaintiff deadline actually control?

 Only who directs the litigation on the class’s behalf. It doesn’t create or remove eligibility for any future recovery.

What specific laws does Regeneron allegedly violate? 

The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

How much could Regeneron investors get if this case resolves?

 Unknown. It depends on proven damages tied to the stock’s decline after the April 29 and May 15, 2026 disclosures, and on how the litigation itself plays out.

Sources Used in This Regeneron Article

• Regeneron Pharmaceuticals, Inc. — Form 10-Q, disclosing the shareholder complaint: https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000025/regn-20260630.htm
• Levi & Korsinsky, LLP — Shareholder alert confirming case caption and number, July 16, 2026: https://www.globenewswire.com/news-release/2026/07/16/3328863/0/en/SHAREHOLDER-ALERT-Levi-Korsinsky-LLP-Notifies-Investors-It-Has-Filed-a-Complaint-to-Recover-Losses-Suffered-by-Purchasers-of-Regeneron-Pharmaceuticals-Inc-Common-Stock-and-Sets-a-L.html

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the sources listed above as of August 3, 2026. Last Updated: August 3, 2026.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.